Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
93 studies found for:    GS-7977 | Gilead [Lead]
Show Display Options
Rank Status Study
1 Completed
Has Results
Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
Condition: Chronic Hepatitis C
Interventions: Drug: SOF;   Drug: RBV;   Drug: Peg-IFN
2 Completed
Has Results
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
Conditions: Hepatitis C;   Human Immunodeficiency Virus
Interventions: Drug: SOF;   Drug: RBV
3 Completed
Has Results
Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
Condition: Hepatitis C
Interventions: Drug: SOF;   Drug: RBV;   Drug: Placebo to match SOF;   Drug: Placebo to match RBV
4 Completed
Has Results
Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Conditions: Hepatitis C;   Hepatocellular Carcinoma
Interventions: Drug: Sofosbuvir;   Drug: Ribavirin
5 Completed
Has Results
Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant
Conditions: Recurrent Chronic Hepatitis C Virus;   Post Liver Transplant
Interventions: Drug: Sofosbuvir;   Drug: RBV
6 Completed
Has Results
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Conditions: Hepatitis C;   Cirrhosis;   Portal Hypertension;   With or Without Liver Decompensation
Interventions: Drug: SOF;   Drug: RBV
7 Completed
Has Results
Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3
Condition: Hepatitis C
Interventions: Drug: SOF;   Drug: PEG;   Drug: RBV
8 Completed
Has Results
Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.
Conditions: Hepatitis C;   HIV
Interventions: Drug: SOF;   Drug: EFV/FTC/TDF;   Drug: EFV;   Drug: ZDV/3TC;   Drug: ATV;   Drug: Ritonavir;   Drug: FTC/TDF;   Drug: DRV;   Drug: RAL;   Drug: PEG;   Drug: RBV
9 Completed
Has Results
Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)
Condition: Chronic Hepatitis C
Interventions: Drug: SOF;   Drug: RBV;   Drug: Placebo to match SOF;   Drug: Placebo to match RBV
10 Completed
Has Results
Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon
Condition: Chronic Hepatitis C
Interventions: Drug: SOF;   Drug: RBV;   Drug: Placebo to match SOF;   Drug: Placebo to match RBV
11 Completed
Has Results
Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection
Condition: Chronic Hepatitis C
Interventions: Drug: Sofosbuvir;   Drug: RBV;   Drug: PEG
12 Recruiting Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis
Condition: Hepatitis C Virus Infection
Interventions: Drug: SOF/VEL;   Drug: RBV
13 Recruiting Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation
Condition: Hepatitis C Virus Infection
Intervention: Drug: SOF/VEL
14 Completed Safety and Efficacy of GS-9857 Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection
Condition: Hepatitis C Virus Infection
Interventions: Drug: GS-9857;   Drug: SOF/VEL
15 Completed Safety and Efficacy of GS-9857 Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection
Condition: Hepatitis C Virus Infection
Interventions: Drug: GS-9857;   Drug: SOF/VEL;   Drug: RBV
16 Completed Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection
Condition: Hepatitis C Virus Infection
Intervention: Drug: SOF/VEL
17 Completed Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis
Condition: Hepatitis C Virus Infection
Interventions: Drug: SOF/VEL;   Drug: RBV
18 Active, not recruiting Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy
Condition: Hepatitis C
Interventions: Drug: SOF/VEL/VOX;   Drug: Placebo
19 Completed Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen
Condition: Hepatitis C Virus Infection
Interventions: Drug: SOF/VEL/VOX;   Drug: RBV
20 Completed
Has Results
Phase 3 Study of Sofosbuvir and Ribavirin
Condition: Hepatitis C
Interventions: Drug: Sofosbuvir;   Drug: PEG;   Drug: RBV

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.